137 related articles for article (PubMed ID: 15934495)
21. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Amato RJ; Malya R; Rawat A
Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
[TBL] [Abstract][Full Text] [Related]
22. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel and vinorelbine plus GM-CSF in malignant melanoma.
Fruehauf JP; Kong KM; Jakowatz JG
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 2):19-22. PubMed ID: 15934496
[TBL] [Abstract][Full Text] [Related]
24. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
[TBL] [Abstract][Full Text] [Related]
25. Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells.
Nasi ML; Lieberman P; Busam KJ; Prieto V; Panageas KS; Lewis JJ; Houghton AN; Chapman PB
Cytokines Cell Mol Ther; 1999 Sep; 5(3):139-44. PubMed ID: 10641571
[TBL] [Abstract][Full Text] [Related]
26. Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastases.
Hoeller C; Jansen B; Heere-Ress E; Pustelnik T; Mossbacher U; Schlagbauer-Wadl H; Wolff K; Pehamberger H
J Invest Dermatol; 2001 Aug; 117(2):371-4. PubMed ID: 11511318
[TBL] [Abstract][Full Text] [Related]
27. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
Westermann J; Reich G; Kopp J; Haus U; Dörken B; Pezzutto A
Cancer Immunol Immunother; 2001 Jan; 49(11):613-20. PubMed ID: 11225992
[TBL] [Abstract][Full Text] [Related]
28. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients.
Ridolfi L; Ridolfi R; Ascari-Raccagni A; Fabbri M; Casadei S; Gatti A; Trevisan G; Righini MG
J Eur Acad Dermatol Venereol; 2001 May; 15(3):218-23. PubMed ID: 11683284
[TBL] [Abstract][Full Text] [Related]
29. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM
J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370
[TBL] [Abstract][Full Text] [Related]
30. In vivo effects of sequential granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-2 (IL-2) on circulating dendritic cells (DC) in patients with surgically resected high risk cutaneous melanoma.
Hasskamp JH; Elias EG; Zapas JL
J Clin Immunol; 2006 Jul; 26(4):331-8. PubMed ID: 16783532
[TBL] [Abstract][Full Text] [Related]
31. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma.
Locke F; Clark JI; Gajewski TF
Cancer Chemother Pharmacol; 2010 Feb; 65(3):509-14. PubMed ID: 19597729
[TBL] [Abstract][Full Text] [Related]
33. Clinical and biological effects of interleukin-2 with or without a concomitant administration of granulocyte-macrophage colony-stimulating factor in metastatic cancer patients.
Lissoni P; Mengo S; Bucovec R; Brivio F; Fumagalli L; Tancini G; Gardani GS
In Vivo; 2003; 17(1):73-5. PubMed ID: 12655794
[TBL] [Abstract][Full Text] [Related]
34. Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients.
Atzpodien J; Fluck M; Reitz M
Cancer Biother Radiopharm; 2004 Dec; 19(6):758-63. PubMed ID: 15665624
[TBL] [Abstract][Full Text] [Related]
35. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
36. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
37. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma.
Hersey P; Menzies SW; Coventry B; Nguyen T; Farrelly M; Collins S; Hirst D; Johnson H
Cancer Immunol Immunother; 2005 Mar; 54(3):208-18. PubMed ID: 15449035
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy With Low-Dose IL-2 in Combination With GM-CSF.
Mier JW
J Immunother; 2003; 26(2):95-6. PubMed ID: 12616100
[No Abstract] [Full Text] [Related]
39. Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial.
Schmidinger M; Steger G; Wenzel C; Locker GJ; Budinsky AC; Brodowicz T; Kramer G; Marberger M; Zielinski CC;
J Immunother; 2001; 24(3):257-62. PubMed ID: 11394504
[TBL] [Abstract][Full Text] [Related]
40. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]